Virtus ETF Advisers’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Virtus ETF Advisers’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,030	Closed	-$404K	–	195
2016 Q3	$404K	Hold	2,030	–	–	0.2%	80
2016 Q2	$263K	Buy	2,030 +610	+43%	+$67.9K	0.2%	79
2016 Q1	$133K	Sell	1,420 -89	-6%	-$9.69K	0.18%	129
2015 Q4	$306K	Buy	+1,509	New	+$270K	0.84%	33

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Virtus ETF Advisers's BLCM Position: Q4 2016 in Review

Virtus ETF Advisers sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2016, closing a stake of 2,030 shares — an estimated $404K sold.

Virtus ETF Advisers first reported a position in BLCM in Q4 2015 and held it in 4 quarters. The position peaked at $404K in Q3 2016. 80 funds tracked by Wall St. Rank hold BLCM as of Q4 2016.

Virtus ETF Advisers reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Virtus ETF Advisers sold 2,030 Bellicum Pharmaceuticals, Inc. shares in Q4 2016, an estimated $404K.
Virtus ETF Advisers first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2015 and held it in 4 quarters.
Virtus ETF Advisers's Bellicum Pharmaceuticals, Inc. position peaked at $404K in Q3 2016.
80 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2016.

Based on Virtus ETF Advisers's 13F filing for Q4 2016, filed 14 Feb 2017.